No photo of Nisha Anjali Mohindra

View Scopus Profile

Nisha Anjali Mohindra

  • 578 Citations
20082020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Training Experience

2012Residency, Northwestern University, Feinberg School of Medicine
2015Fellowship, Northwestern University, Feinberg School of Medicine

Education/Academic qualification

MD, University of Texas Southwestern Medical Center

… → 2009

Fingerprint Dive into the research topics where Nisha Anjali Mohindra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II Lymph-node Negative

Mohindra, N. A.

AstraZeneca Pharmaceuticals LP

12/20/19 → 12/20/22

Project: Research project

54679793: Using the Novel 4R Patient Care Sequences to Improve the Duration and Outcomes of NSCLC Patients Receiving Targeted Treatment

Mohindra, N. A.

Pfizer Inc.

12/16/19 → 12/31/21

Project: Research project

Prot #M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Mohindra, N. A.

AbbVie Inc.

12/4/19 → 12/4/20

Project: Research project

Prot #BO39633: An Open-Label, Multicenter Extension and Long-Term Observational Study In Patients Previously Enrolled in a Genentech- and/or F. Hoffman-La Roche Ltd-Sponsored Atezolizumab Study

Mohindra, N. A.

Syneos Health, Inc., Genentech, Inc. and Hoffmann-La Roche Inc.

8/30/18 → 8/30/21

Project: Research project

Prot #CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Mohindra, N. A.

Bristol-Myers Squibb Company

8/28/17 → 8/28/20

Project: Research project

Research Output

Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, B. H., Lunning, M., McGettigan, S., McPherson, J., Mohindra, N. A., Naidoo, J., Olszanski, A. J., Oluwole, O. & 12 others, Patel, S. P., Pennell, N., Reddy, S., Ryder, M., Santomasso, B., Shofer, S., Sosman, J. A., Wang, Y., Weight, R. M., Johnson-Chilla, A., Zuccarino-Catania, G. & Engh, A., Jan 1 2020, In : JNCCN Journal of the National Comprehensive Cancer Network. 18, 3, p. 231-241 11 p.

Research output: Contribution to journal › Article

Open Access
    • 2 Scopus citations

    Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib

    Principe, D. R., Kamath, S. D., Munshi, H. G. & Mohindra, N. A., Apr 1 2020, In : Oncologist. 25, 4, p. 301-305 5 p.

    Research output: Contribution to journal › Article

    Open Access

    • Alveolar soft part sarcoma mimics prostate cancer metastasis

    Principe, D. R., Mohindra, N. A., Munshi, H. G. & Kamath, S. D., Dec 1 2019, In : Oxford Medical Case Reports. 2019, 12, p. 507-509 3 p.

    Research output: Contribution to journal › Article

    Open Access

    • A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials

    Shaikh, S. S., Kumthekar, P. U. & Mohindra, N. A., Aug 15 2019, In : Journal of Neuro-Oncology. 144, 1, p. 235-237 3 p.

    Research output: Contribution to journal › Letter

    Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

    Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N., Villaflor, V. & Giles, F., Mar 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

    Research output: Contribution to journal › Article

    • 15 Scopus citations